

Efficacy and Safety Phase III Clinical Study of VC005 Tablets in Subjects With Active Ankylosing Spondylitis.

NCT07172360

Status	RECRUITING
Phase	Phase 3
Sponsor	Jiangsu vcare pharmaceutical technology co., LTD
Enrollment	420 participants

Key Eligibility Criteria

Inclusion (3)

- The subject understands and voluntarily signs the informed consent form (ICF) and is willing and able to comply with the study protocol;
- The subject is between 18 and 70 years of age (including borderline values) at the time of signing the ICF, regardless of gender;
- The subject has been diagnosed with AS according to the 1984 New York Revised Criteria for Ankylosing Spondylitis

Exclusion (3)

- Those who may be allergic to VC005, similar drugs or their excipients.
- Individuals who have undergone organ transplantation in the past and require continuous use of immunosuppressants.
- Those who, for any reason, are considered by the investigator to be unsuitable for participation in this study.

Locations (1 total)

Peking University People's Hospital, Beijing, Beijing Municipality, China